Skip to main content

Tezspire Side Effects

Generic name: tezepelumab

Medically reviewed by Drugs.com. Last updated on May 29, 2023.

Note: This document contains side effect information about tezepelumab. Some dosage forms listed on this page may not apply to the brand name Tezspire.

Applies to tezepelumab: subcutaneous solution.

Serious side effects of Tezspire

Along with its needed effects, tezepelumab (the active ingredient contained in Tezspire) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tezepelumab:

Incidence not known

Other side effects of Tezspire

Some side effects of tezepelumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to tezepelumab: subcutaneous solution.

General

The most common adverse reactions included pharyngitis, arthralgia, and back pain. The safety profile in pediatric patients was generally similar to the overall study population.[Ref]

Cardiovascular

Frequency not reported: MACE (major adverse cardiovascular events)

One clinical trial observed higher incidence rates per 100 patient-years for both serious cardiac adverse events and MACE in patients treated with this drug as compared to placebo; however, the clinical implications of these findings were not described by the manufacturer.

Dermatologic

Rash included rash, pruritic rash, erythematous rash, maculopapular rash, and macular rash.

Common (1% to 10%): Rash

Hypersensitivity

Postmarketing reports: Anaphylaxis

Immunologic

Common (1% to 10%): Anti-drug antibodies

Local

Common (1% to 10%): Injection site reactions

Injection site reactions included injection site erythema, injection site swelling, and injection site pain.

In one clinical study, injection site reactions were observed in a higher percentage of patients who used the prefilled pen (5.7%) versus the prefilled syringe (0%).

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain

Respiratory

Common (1% to 10%): Pharyngitis

Pharyngitis included pharyngitis, bacterial pharyngitis, streptococcal pharyngitis, and viral pharyngitis.

Frequently asked questions

References

1. Product Information. Tezspire (tezepelumab). Amgen USA. 2021.

2. Product Information. Tezspire (tezepelumab). AstraZeneca UK Ltd. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.